Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


RTX Healthcare gets US nod for Telehealth monitor:

This article was originally published in Clinica

Executive Summary

RTX Healthcare has received 510(k) clearance from the US FDA for its RTX3370 Telehealth monitor for patients outside hospitals. The system, designed to allow patients with chronic diseases to live more independently, monitors patients' vital signs from peripheral devices and collates subjective patient information from questionnaires; it then transmits the data to a central clinical information system. Peripheral devices that can be used with the Telehealth Monitor include scales, blood pressure monitors, blood glucose meters, peak flow meters and oxygen saturation meters. Noerresundby, Denmark-based RTX recently joined the Continua Health Alliance - a non-profit group working towards deciding the best technical standards for home healthcare monitoring. RTX Healthcare is a division of Nordic-listed company RTX Telecom.

You may also be interested in...

European Firms Adapting To Coronavirus Challenges

Companies across Europe are dealing with new challenges stemming from the coronavirus outbreak, particularly with supply issues due to increased demand. This article details the responses of five consumer health players in the region: Reckitt Benckiser, Zentiva, Vitabiotics, Alliance Pharma and BioGaia.

COVID-19 Pandemic Accelerates Shift Toward Virtual Trials

As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation. 

mRNA Vaccines – Trials Line Up Against Coronavirus

The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts